The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

Company Observatory

LMAT

LeMaitre Vascular, Inc.

Healthcare · Medical - Instruments & Supplies

Overall research band Weak
Quality Strong
Valuation Weak
Balance sheet Weak
Market confirmation Very weak

One-minute company read

What this report can tell you now

What the company does

LeMaitre Vascular, Inc. develops, distributes, and maintains medical devices and implants for the treatment of peripheral vascular disease. Its product range includes various catheters—such as angioscopes for vessel visualization, embolectomy catheters for clot removal, occlusion catheters to temporarily stop blood flow, perfusion catheters for fluid infusion, and thrombectomy catheters for extracting venous thrombi—as well as carotid shunts for redirecting blood flow during surgery, radiopaque tape for anatomical cross-referencing, valvulotomes for preparing veins for arterial bypass, vascular grafts for bypassing or replacing arteries, and vascular and cardiac patches for vessel closure. The company also offers closure systems using titanium clips as an alternative to sutures. LeMaitre Vascular serves healthcare providers worldwide through a combination of direct sales and distributor networks, generating revenue from the sale of its specialized medical devices and implants.

The current research profile is Premium Growth, with valuation sensitive. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Business quality is the strongest visible dimension. Check valuation before treating that strength as an investment conclusion.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC10.0%Model input; read with the evidence status and period context.
Operating margin27.2%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years12.8%Model input; read with the evidence status and period context.
FCF margin29.8%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.